Current status and future perspectives for yttrium-90 (90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma

Bone Marrow Transplantation

Volumn 40, Issue 11, 2007, Pages 1007-1017

  Gisselbrecht, C ^a   Bethge, W ^b   Duarte, R F ^c   Gianni, A M ^d   Glass, B ^e   Haioun, C ^f   Martinelli, G ^g   Nagler, A ^h   Pettengell, R ⁱ   Sureda, A ^j   Tilly, H ^k   Wilson, K ^l  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c HOSPITAL DURAN I REYNALS   (Spain)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^f HENRI MONDOR HOSPITAL   (France)

^g EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^h SHEBA MEDICAL CENTER   (Israel)

ⁱ ST GEORGE S HOSPITAL   (United Kingdom)

^j UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^k CENTRE HENRI BECQUEREL   (France)

^l CARDIFF UNIVERSITY   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IBRITUMOMAB TIUXETAN; MELPHALAN; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE;

ALLERGIC REACTION; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RELAPSE; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ERYTHROCYTE TRANSFUSION; EUROPE; FEBRILE NEUTROPENIA; FEVER; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOTHERAPY; INFECTION; ISOTOPE LABELING; LIVER TOXICITY; LUNG TOXICITY; MONOTHERAPY; MYELOABLATIVE CONDITIONING; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; PRIORITY JOURNAL; RADIATION DOSE; RASH; REDUCED INTENSITY CONDITIONING; REVIEW; SIDE EFFECT; STOMATITIS; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THYROTROPIN BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION;

ANTIBODIES, MONOCLONAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; LYMPHOMA, NON-HODGKIN; MYELOABLATIVE AGONISTS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 36349020774     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705868     Document Type: Review

References (58)

1. Hahn T, Wall D, Camitta B, Davies S, Dillon H, Gaynon P et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: An evidence-based review. Biol Blood Marrow Transplant 2006; 12 1-30.
2. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
3. Ladetto M, Ricca I, Benedetti F, Vitolo U, Patti C, Rambaldi A et al. Rituximab-supplemented high-dose sequential chemotherapy (HDS) has superior response rate and event-free survival (EFS) compared to R-CHOP in poor risk follicular lymphoma (FL) at diagnosis: Results from a multicenter randomized GITMO trial. Blood 2005; 106, abstract 675.
4. Shimoni A, Hardan I, Avigdor A, Yeshurun M, Raanani P, Ben Bassat I et al. Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma. Br J Haematol 2003; 122: 457-464.
5. Bitran JD, Klein L, Link D, Kosirog-Glowacki J, Stewart C, Raack D et al. High-dose myeloablative therapy and autologous peripheral blood progenitor cell transplantation for elderly patients (greater than 65 years of age) with relapsed large cell lymphoma. Biol Blood Marrow Transplant 2003; 9: 383-388.
6. Villela L, Sureda A, Canals C, Sanz Jr MA, Martino R, Valcarcel D et al. Low transplant related mortality in older patients with hematologic malignancies undergoing autologous stem cell transplantation. Haematologica 2003; 88: 300-305.
7. Buadi FK, Micallef IN, Ansell SM, Porrata LF, Dispenzieri A, Elliot MA et al. Autologous hematopoictic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 2006; 37: 1017-1022.
8. Gopal AK, Gooley TA, Golden JB, Maloney DG, Bensinger WI, Petersdorf SH et al. Efficacy of high-dose therapy and autologous hematopoictic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older. Bone Marrow Transplant 2001; 27: 593-599.
9. Mileshkin LR, Seymour JF, Wolf MM, Gates P, Januszewicz EIL Joyce P et al. Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older. Leak Lymphoma 2005; 46: 1575-1579.
10. Khouri IF. Reduced-intensity regimens in allogeneic stem-cell transplantation for non-Hodgkin lymphoma and chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2006, 390-397.
11. Peniket AJ, Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, de Witte T et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: Allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31: 667-678.
12. Bierman PJ, Sweetenham JW, Loberiza Jr FR, Taghipour G, Lazarus HM, Rizzo JD et al. Syngeneic hematopoictic stem-cell transplantation for non-Hodgkin's lymphoma: A comparison with allogeneic and autologous transplantation - The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 2003; 21: 3744-3753.
13. Hosing C, Saliba RM, McLaughlin P, Andersson B, Rodriguez MA, Fayad L et al. Long-term results favor allogeneic over autologous hematopoictic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma. Ann Oncol 2003; 14 737-744.
14. Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 2000; 25: 1021-1028.
15. Kahl C, Storer BE, Sandmaier BM, Mielcarek M, Maris MB, Blume KG et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007; e-pub ahead of print, 26 June 2007.
16. Smith SM. Reduced-intensity transplantation for lymphoma. Curr Treat Options Oncol 2006; 7: 295-305.
17. Vigouroux S, Michallet M, Porcher R, Attal M, Ades L, Bernard M et al. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: A survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica 2007; 92: 627-634.
18. Baron F, Storb R, Storer BE, Maris MB, Niederwieser D, Shizuru JA et al. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J. Clin Oncol 2006; 24: 4150-4157.
19. Cheung MC, Haynes AE, Stevens A, Meyer RM, Imrie K. Yttrium 90 ibritumomab tiuxetan in lymphoma. Leuk Lymphoma 2006; 47: 967-977.
20. Hagenbeek A, Lewington V. Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma. Ann Oncol 2005; 16: 786 792.
21. Weigert O, Illidge T, Hiddemann W, Dreyling M. Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma. Cancer 2006; 107: 686-695.
22. Witzig TE. Radioimmunotherapy for B-cell non-Hodgkin lymphoma. Best Pract Res Clin Haematol 2006; 19: 655-668.
23. Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL et al. Safety of yttrium-90 ibritumomab tiuxetan radiommumotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 2003; 21: 1263-1270.
24. Shimoni A, Zwass T, Oksman Y, Hardan I, Shem-Tov N, Yerushalmi R et al. Yttrium-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem-cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. Exp Hematol 2007; 35: 534-540.
25. 90Y ibritumomab tiuxetan with high dose chemotherapy in elderly patients with non Hodgkin's lymphoma (NHL). J Clin Oncol 2005; ASCO Annual Meeting Proceedings 23[16S], abstract 6566.
26. Krishnan A, Raubitschek A, Forman SJ, Fung H, Molina A, Yamauchi D et al. New transplant strategies utilizing radioimmunotherapy (RIT) based regimens to reduce relapse in high risk mantle cell lymphoma (MCL). Blood 2005; 106, abstract 681.
27. Krishnan AK, Raubitschek AR, Forman S, Fung HF, Molina AM, Yamauchi DY et al. Transplant regimens for high-risk mantle cell lymphoma: The effect of incorporating ibritumomab tiuxetan radiommumotherapy on relapse rate. Haematologica 2006; 91 (Suppl 1), abstract 0209.
28. Krishnan AY, Nademanee A, Raubitschek A, Fung HC, Molina A, Yamauchi D et al. A comparison of BEAM and yttrium 90 ibritumomab tiuxetan (Zevalin) in addition to BEAM (Z-BEAM) in older patients undergoing autologous stem cell transplant (ASCT) for B-cell lymphomas: Impact of radiommumotherapy on transplant outcomes. Blood 2006; 108, abstract 3043.
29. 90Y) ibritumomab tiuxetan in autologous and nonmyeloablative stem cell transplantation (NST) for relapsed non-Hodgkin's lymphoma (NHL). Blood 2006; 108, abstract 315.
30. Vose JM, Bierman PJ, Enke C, Hankins J, Bociek G, Lynch JC et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 461-467.
31. Wiseman GA, White CA, Sparks RB, Erwin WD, Podoloff DA, Lamonica D et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radiommumotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol 2001; 39: 181-194.
32. Nademanee A, Forman S, Molina A, Fung H, Smith D, Dagis A et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 2005; 106: 2896-2902.
33. Winter JN, Inwards DJ, Spies S, Wiseman G, Patton D, Erwin W et al. Y ibritumomab tiuxetan (Zevaling® 90YZ) doses higher than 0.4mCi/kg may be safely combined with high-dose BEAM and autotransplant: The role for dosimetry. Blood 2004; 104, abstract 1162.
34. Winter J, Inwards D, Spies S, Wiseman G, Patton D, Erwin W et al. Zevalin (90YZ) doses>0.5mCi/kg may be combined with high-dose BEAM and autotransplant (ASCT). ICML 2005 Proceedings; Ann Oncol 16: V95 V104 (abstract 215).
35. Winter JN, Inwards D, Spies S, Wiseman G, Patton D, Erwin W et al. Y ibritumomab tiuxetan (Zevalin; 90YZ) doses calculated to deliver up to 1500 cGy to critical organs may be safely combined with high-dose BEAM and autotransplant in NHL. Blood 2006; 108, abstract 330.
36. Press OW, Eary JF, Gooley T, Gopal AK, Liu S, Rajendran JG et al. A phase I/II trial of iodine-131-tositumomab (anti CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000; 96: 2934-2942.
37. Gopal AK, Rajendran JG, Petersdorf SH, Maloney DG, Eary JF, Wood BL et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002; 99: 3158-3162.
38. Devizzi L, Seregni E, Guidetti A, Forni C, Coliva A, Magni M et al. High-dose myeloablative Zevalin radiommumotherapy with tandem stem-cell autografting has minimal toxicity and full feasibility in an outpatient setting. Blood 2005; 106, abstract 2737.
39. Devizzi L, Seregni E, Guidetti A, Forni C, Coliva A, Magm M et al. High-dose myeloablative Zevalin radiommumotherapy with tandem stem-cell autografting has promising activity, minimal toxicity and full feasibility in an outpatient setting. Blood 2006; 108, abstract 3047.
40. Vanazzi A, Ferrucci PF, Ferrari M, Calabrese L, Cremonesi M, Bartolomei M et al. High dose Zevalin (90Yttrium ibritumomab tiuxetan) treatment with PBSC support in refractory-resistant NHL patients: preliminary results of a phase I/II study. Blood 2005; 106, abstract 488.
41. Vanazzi A, Ferrucci PF, Grana C, Cremonesi M, Clerici M, Radice D et al. High dose 90Yttrium ibritumomab tiuxetan (Zevalin) with PBSC support in refractory-resistant NHL patients: A phase I/II study. Blood 2006; 108, abstract 2720.
42. Vanazzi A, Ferrucci P, Grana C, Cremonesi M, Chinol M, Papi S et al. High dose 90Yttrium ibritumomab tiuxetan with PBSC support in refractory-resistant NHL patients: Preliminary results of a phase I/II study. J Clin Oncol 2006; ASCO Annual Meeting Proceedings Part I. 24[18S], abstract 7587.
43. Flinn I. Dose finding trial of yttrium 90 ibritumomab tiuxetan (90YIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). J Clin Oncol 2006; ASCO Annual Meeting Proceedings Part I 24[18S], abstract 7535.
44. 90Y) ibritumomab tiuxetan with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). Blood 2004; 104 abstract 897.
45. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329: 1219-1224.
46. Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995; 346: 336-340.
47. Liu SY, Eary JF, Petersdorf SH, Martin PJ, Maloney DG, Appelbaum FR et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 anti-body and autologous stem-cell rescue. J Clin Oncol 1998; 16: 3270-3278.
48. Behr TM, Griesinger F, Riggert J, Gratz S, Behe M, Kaufmann CC et al. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study. Cancer 2002; 94: 1363-1372.
49. Hohloch K, Wulf G, Jung W, Stitz E, Meller J, Glass B et al. Tandem HD-chemotherapy and myeloablative radioimmunotherapy with 131I-anti-CD20 rituximab in relapsed and refractory B-cell lymphoma: results of a phase II study of the German RAIT study group. J Clin Oncol 2006; ASCO Annual Meeting Proceedings Part I 24, abstract 13007.
50. 131I]tositumomab (anti-CD20) radiommumotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol 2007; 25: 1396-1402.
51. Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003; 21: 897-906.
52. Czuczman MS, Emmanouilides C, Darif M, Witzig TE, Gordon LI, Revell S et al. Analysis of the incidence of treatment-related myelodysplastic syndrome and acute myelogenous leukaemia in registration and compassionate-use trials of ibritumomab tiuxetan radioimmumotherapy (RIT). Blood 2006; 180, abstract 485.
53. Otte A, Dierckx RA. Myelosuppressive side-effects of radioimmunotherapy of non-Hodgkin's lymphoma: Is there an increased risk? Nucl Med Commun 2005; 26: 1045-1047.
54. Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 2005; 105 4576-4582.
55. 90Y-ibritumomab-tiuxetan. Leuk Lymphoma 2006; 47: 59-63.
56. Shimoni A, Zwas T, Oksman Y, Hardan I, Shem-Tov N, Yerushalmi R et al. Ibritumomab tiuxetan (Zevalin) in the conditioning regimen for autologous and reduced-intensity allogeneic stem-cell transplantation in patients with chemorefractory non-Hodgkin's lymphoma. Blood 2005; 106, abstract 1131.
57. Shimoni A, Zwas T, Oksman Y, Hardan I, Shem-Tov N, Yerushalmi R et al. lbritumomab tiuxetan (Zevaling) combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with chemo-refractory non-Hodgkin lymphoma. Bone Marrow Transplant 2007; 39 (Suppl 1s), abstract P511.
58. 90Y-ibritumomab tiuxetan-based reduced intensity allogeneic peripheral blood stem cell (PBSC) transplantation for relapsed CD20 + B-cell non-Hodgkin's lymphoma (NHL). Blood 2006; 108, abstract 316.